DCT

1:26-cv-00854

MyoKardia Inc v. DR Reddys Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00854, D. Del., 07/14/2026
  • Venue Allegations: Venue is alleged to be proper based on Defendants being subject to personal jurisdiction in the district. The complaint also notes that Defendants regularly engage in and do not contest venue in patent litigation in the District of Delaware.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' drug Camzyos® (mavacamten) constitutes an act of patent infringement.
  • Technical Context: The technology relates to small-molecule cardiac myosin inhibitors used for the treatment of hypertrophic cardiomyopathy, a disease characterized by the thickening of the heart muscle.
  • Key Procedural History: The lawsuit was triggered by a notice letter, dated June 5, 2026, in which Defendant Dr. Reddy's Laboratories, Ltd. informed Plaintiffs of its ANDA submission. This submission included a "Paragraph IV" certification asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic product.

Case Timeline

Date Event
2013-06-21 Earliest Priority Date for RE'050 and '883 Patents
2017-03-07 U.S. Patent No. 9,585,883 Issues
2024-07-23 U.S. Reissue Patent No. 50,050 Issues
2026-06-05 Defendant's ANDA Notice Letter Dated
2026-07-14 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 50,050 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Reissue Patent No. 50,050 ("Pyrimidinedione Compounds"), issued July 23, 2024.

The Invention Explained

  • Problem Addressed: The patent family addresses hypertrophic cardiomyopathy (HCM), a genetic cardiac disorder that causes thickening of the heart muscle, leading to excess contractility, impaired heart relaxation (diastolic dysfunction), and potential outflow obstruction US 9,585,883 B2, col. 1:44-59
  • The Patented Solution: The invention provides novel pyrimidine dione compounds, including mavacamten, that act as cardiac myosin inhibitors Compl. ¶32 These compounds are designed to reduce excess contractility and promote cardiac relaxation by stabilizing the conformation of beta cardiac myosin, thereby reducing the proportion of myosin molecules available to participate in the power-generating portion of the muscle contraction cycle US 9,585,883 B2, col. 3:25-39
  • Technical Importance: This approach represents a targeted therapy that directly addresses the underlying hypercontractility mechanism of HCM, as opposed to merely managing symptoms US 9,585,883 B2, col. 17:45-51

Key Claims at a Glance

  • The complaint asserts at least claim 20 Compl. ¶37
  • The complaint alleges that claim 20 is a compound claim that covers mavacamten Compl. ¶32 Compl. ¶33 The specific text of the claim is not provided in the complaint.

U.S. Patent No. 9,585,883 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Patent No. 9585883 ("Pyrimidinedione Compounds"), issued March 7, 2017.

The Invention Explained

  • Problem Addressed: The '883 Patent addresses the need for treatments for HCM and related conditions associated with diastolic dysfunction US 9,585,883 B2, col. 1:44-59
  • The Patented Solution: The patent describes methods of treating HCM by administering an effective amount of a pyrimidine dione compound US 9,585,883 B2, abstract These compounds, such as mavacamten, function by reducing the number of myosin heads available for the "powerstroke" in the muscle contraction cycle, which improves the heart's ability to relax US 9,585,883 B2, col. 3:25-39 The synthesis of these compounds is detailed in the specification US 9,585,883 B2, FIG. 1A
  • Technical Importance: The patented method provides a way to directly modulate the sarcomere, the basic contractile unit of heart muscle, offering a disease-modifying therapy for a genetic heart condition US 9,585,883 B2, col. 17:51-61

Key Claims at a Glance

  • The complaint asserts at least claim 18, which depends on independent claim 1 Compl. ¶53
  • Independent Claim 1 of the '883 Patent recites:
    • A method of treating hypertrophic cardiomyopathy (HCM),
    • comprising administering to a subject in need thereof an effective amount of a compound having a specified chemical formula, or a pharmaceutically acceptable salt thereof.
  • The complaint notes that claim 18 specifically covers the use of the compound mavacamten for the claimed method Compl. ¶52 Compl. ¶53

III. The Accused Instrumentality

Product Identification

  • Defendants' proposed generic version of Camzyos® (mavacamten) capsules, in 2.5 mg, 5 mg, 10 mg, and 15 mg dosages ("DRL's ANDA Product") Compl. ¶2

Functionality and Market Context

  • DRL's ANDA Product contains the active ingredient mavacamten, which is a cardiac myosin inhibitor used to treat adults with obstructive hypertrophic cardiomyopathy Compl. ¶27
  • As an ANDA product, it is a generic version of the branded drug Camzyos® and is intended to be a lower-cost, bioequivalent alternative Compl. ¶2 Compl. ¶28 The complaint alleges the product would be manufactured, used, and sold upon receiving FDA approval Compl. ¶40

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

RE'050 Patent Infringement Allegations

Claim Element (from Asserted Claim 20) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound, which is mavacamten DRL's ANDA Product contains the active ingredient mavacamten Compl. ¶27 ¶37 US 9,585,883 B2, col. 9:18-20; col. 6:11-44

'883 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating hypertrophic cardiomyopathy (HCM) DRL's proposed product labeling for its ANDA Product will direct the use of the product for treating HCM, the same indication as the branded drug Camzyos® Compl. ¶27 Compl. ¶52 Compl. ¶58 ¶58 col. 17:62-64
comprising administering to a subject in need thereof an effective amount of a compound [mavacamten]... DRL's ANDA Product contains mavacamten, and its proposed labeling will instruct patients and physicians on its administration in effective amounts Compl. ¶27 Compl. ¶52 Compl. ¶57 ¶57 col. 9:18-20; col. 18:65-68
  • Identified Points of Contention:
    • Statutory Infringement: This is a Hatch-Waxman Act case where the act of filing an ANDA with a Paragraph IV certification is a statutory act of infringement (35 U.S.C. § 271(e)(2)). The core of the case will not be a technical dispute over whether the generic product meets the claim limitations-as a bioequivalent copy, it is intended to. Instead, the central dispute will be over the validity of the patents-in-suit.
    • Validity Questions: Defendants have certified that the patents are invalid and/or unenforceable Compl. ¶35 Compl. ¶55 While the complaint does not detail Defendants' invalidity theories, these will likely form the main defense and will focus on issues such as whether the claimed compound and methods were anticipated by prior art or would have been obvious to a person of ordinary skill at the time of the invention.
    • Reissue Patent Defenses: For the RE'050 patent, a potential point of contention, common in litigation involving reissue patents, is whether the reissued claims improperly recapture subject matter that was surrendered during the original prosecution.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a deep analysis of claim construction disputes. However, based on the technology and asserted claims, certain terms may become focal points.

  • The Term: "treating" (from claim 1 of the '883 Patent)
  • Context and Importance: The definition of "treating" is fundamental to the scope of the method claim. A broad definition would cover a wide range of clinical outcomes, while a narrow one might require a specific therapeutic result. Practitioners may focus on this term to determine if the outcomes described in Defendants' proposed label fall squarely within the patent's definition.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides an explicit and broad definition, stating that "treat," "treating," and "treatment" refer to "any indicia of success in the treatment or amelioration of a pathology, injury, condition, or symptom... including any objective or subjective parameter such as abatement; remission; [or] diminishing of symptoms" US 9,585,883 B2, col. 5:49-56
    • Evidence for a Narrower Interpretation: A defendant might argue that the term should be limited to the specific clinical benefits highlighted in the detailed description, such as improving ventricular relaxation or reducing outflow obstruction, rather than any general "indicia of success" US 9,585,883 B2, col. 18:7-10

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval, DRL will induce infringement of the '883 patent because its proposed product labeling will instruct medical professionals and patients to use the generic product in a manner that practices the claimed method of treating HCM Compl. ¶62 The complaint also alleges contributory infringement, stating the product is not a staple article of commerce and is not suitable for substantial non-infringing use Compl. ¶59 Compl. ¶64
  • Willful Infringement: The complaint does not use the word "willful" but alleges that Defendants have knowledge of the patents-in-suit, citing the listing of the patents in the FDA's Orange Book and the receipt of the notice letter Compl. ¶42 Compl. ¶63 It further alleges that notwithstanding this knowledge, DRL intends to manufacture and sell the infringing product prior to patent expiration Compl. ¶42 Compl. ¶63 Plaintiffs also seek a declaration that this is an exceptional case, which is often associated with findings of willful infringement or litigation misconduct Prayer for Relief ¶i

VII. Analyst's Conclusion: Key Questions for the Case

This litigation appears to be a standard Hatch-Waxman dispute initiated in response to a Paragraph IV challenge. The case will likely center on the following questions:

  1. Patent Validity: The primary issue for the court will be whether Defendants can prove by clear and convincing evidence that the asserted claims of the RE'050 and '883 patents are invalid for anticipation or obviousness over the prior art. This is the central defense in a Paragraph IV case.
  2. Infringement by Label: A secondary question, though often less contentious in ANDA cases, will be one of induced infringement: does the specific language in Defendants' proposed product label, which is expected to mirror the branded drug's label, instruct users to perform all steps of the method claimed in the '883 patent?
  3. Reissue Recapture Doctrine: A specific defense against the RE'050 patent may arise concerning impermissible recapture: did the patentee, in obtaining the reissued claims, attempt to reclaim subject matter that was surrendered during the prosecution of the original patent to overcome a prior art rejection?
Loading Complaint